Trial · NCT05886582
Transdermal Rotigotine as Adjunct to Behavioral Therapy for Cocaine Use Disorder
NCT05886582, Phase 2, Completed, Virginia Commonwealth University
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Transdermal Rotigotine as Adjunct to Behavioral Therapy for Cocaine Use Disorder. Trials, record NCT05886582. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05886582
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Transdermal Rotigotine as Adjunct to Behavioral Therapy for Cocaine Use Disorder
- NCT number
- NCT05886582
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 50 participants, actual
- Lead sponsor
- Virginia Commonwealth University
- Conditions
- Substance-Related Disorders
- Interventions
- Rotigotine Transdermal System [Neupro], Placebo
- First posted
- 2023-06-02
- Last updated
- 2026-08-31
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Cocaine-positive urine samples | weeks 5 - 6 of transdermal patch treatment | comparison of cocaine-positive urine samples between participants randomized to transdermal RTG relative to participants randomized to placebo patches |
| Primary | self-reported cocaine use | weeks 5 - 6 of transdermal patch treatment | comparison of cocaine cocaine use (by self report) between participants randomized to transdermal RTG relative to participants randomized to placebo patches |
| Secondary | executive function (change) | change from baseline to study week 6 | Change in CNS-VS Neurocognition Index (NCI) scores |
| Secondary | QoLI total score (change) | change from baseline to study week 6 | Change in QoLI total scores |
| Secondary | dorsolateral prefrontal cortex (DLPFC) | study day 1 to study week 6 | Change in recruitment of dorsolateral prefrontal cortex (DLPFC) |
| Secondary | stop signal task (SST) | study day 1 to study week 6 | Change in recruitment of right anterior insula by stop-signals in the SST |
| Secondary | EC from DLPFC to striatum during working memory demands | study day 1 to study week 6 | change in EC from DLPFC to striatum during working memory demands in the EFNBk and during resting state |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| U01DA057846 | Transdermal Rotigotine as Adjunct to Behavioral Therapy for Cocaine Use Disorder | BJORK, JAMES M; ARIAS, ALBERT JOSEPH | VIRGINIA COMMONWEALTH UNIVERSITY | NATIONAL INSTITUTE ON DRUG ABUSE | 2022 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as |
|---|---|
| Stop-Signal Task | Secondary outcome |
Source ConductCognition
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05886582
GET https://conductscience.org/api/trials/v1/NCT05886582/registered